Last Updated : May 22, 2019
Details
FilesProject Line:
Health Technology Review
Project Number:
HE0013-000
Prolastin-C is an alpha1-proteinase inhibitor (A1-PI) that received its Notice of Compliance in Canada in 2010; this product replaced an older A1-PI formulation called Prolastin. Other A1-PI products available globally include Aralast and Respreeza/Zemaira.
Patients with alpha1-antitrypsin (AAT) deficiency have low AAT levels. Intravenous infusion of Prolastin-C aims to normalize AAT levels in these patients. As some patients with severe AAT deficiency may develop chronic obstructive pulmonary disease, in particular emphysema, drug therapy to augment AAT levels may help to inhibit lung tissue destruction, which may help to maintain lung function.
Canadian jurisdictions were interested in better understanding the pharmacoeconomic value of Prolastin-C and thus a review of published economic evaluations was undertaken.
Files
Last Updated : May 22, 2019